WILEX shares successfully placed at EUR 13.80

10 November, 2006

Munich (Germany)– The Munich-based biopharmaceutical company WILEX AG (ISIN DE0006614720; WKN 661472), together with WestLB AG, Düsseldorf as Bookrunner and Sal. Oppenheim jr. & Cie. Kommanditgesellschaft auf Aktien, Köln, as Co-Lead Manager today announced the placing price of its offered shares as well as additional details regarding the allotment of shares. The offering price has been fixed at EUR 13.80 per share. 4.6 million shares including an over-allotment option (greenshoe) were placed in the offering. 4,000,000 shares result from a capital increase resolved by the ordinary shareholders' meeting on September 11, 2006. The 600,000 shares for the over-allotment option were lent by an existing shareholder through a share loan agreement. Should the over-allotment option be exercised, the executive management board, with the approval of the supervisory board, will resolve the issuance of the appropriate number of ordinary bearer shares through a capital increase from authorised capital.

The shares were placed with institutional investors throughout Europe. As part of the placement existing shareholders HDP Beteiligungs GmbH (HDP) and Funds managed by TVM Capital GmbH (TVM) subscribed to and were allotted shares in addition to those shares already held before the offering. Through this both HDP and TVM reinforce their long term commitment to the company. The number of shares held by HDP will increase from 2,041,953 shares to 3,411,953 shares. HDP’s holding will be 28.5% without exercise of the Greenshoe option and 27.2% if the Greenshoe is exercised in full. The number of shares held by TVM will increase from 853,355 shares to 925,819 shares. TVM’s holding will be 7.7% without exercise of the Greenshoe option and 7.4% if the Greenshoe is exercised in full. The shares subscribed by and allotted to the above investors in the offering will not be subject to the lock-up agreements signed by existing shareholders regarding shares held before the offering. Including the shares subscribed for and allotted to HDP and TVM the free float of the company will be approximately 36.6%. Private investors were not allotted any shares.

The issue volume is approximately EUR 63.5 million including the over-allotment shares. The company raised approximately EUR 55.2 million from the capital increase of 4 million shares (before transaction costs). In case of a complete exercise of the over-allotment option the company will raise an additional EUR 8.3 million (before transaction costs). Trading is expected to begin on November 13, 2006 in the Prime-Standard of the regulated market of the Frankfurt stock exchange.

“We will use the raised funds to develop WILEX into a profitable biopharmaceutical company with a broad portfolio of new medical products for the treatment of cancer”, said Prof. Olaf Wilhelm, CEO of the company. “So far all the test results of our product candidates have in our view been outstanding. We have reached some important milestones so far and we look forward to realising several additional milestones in the next 18 months. The IPO is an important next step in the development of our company.”

About WILEX

WILEX is a biopharmaceutical Company based in Munich, which was founded in 1997 by a team of physicians and oncologists from the Technical University of Munich. WILEX is focused on the development of new cancer therapies based on antibodies and small molecules. The therapeutic approach of WILEX targets the prevention of growth, spread and the metastasis of malignant tumours and the destruction of malig-nant tumours in the body. The portfolio includes both drug and medical product candidates ranging from research to late stage clinical development. Currently the following compounds are in clinical development: WX-G250 (development name: RENCAREX®), WX-671, WX-UK1 and CA9-SCAN. The company’s strategy is to develop WILEX into a commercially successful biopharmaceutical company with a broad portfolio of new drugs and medical products for the treatment of cancer.

Contact

Juliane Giese
Manager Public Relations
WILEX AG
Grillparzerstr. 16
81675 Munich
Germany
Tel.: +49 (0)89-41 31 38-29
Fax: +49 (0)89-41 31 38-99
Email: juliane.giese@wilex.com

Please note:

This document constitutes neither an offer to sell nor a solicitation to buy securities of WILEX AG. The securities have already been sold.

This document is not an offer to buy securities in the United States of America. Securities may only be sold or offered for purchase in the United States of America with prior registration subject to the provisions of the US Securities Act 1933 in the currently-valid version, or in the absence of prior registration, only on the basis of an exception. Shares in WILEX AG are not and will not be registered pursuant to the provisions of the US Securities Act 1933 in the currently-valid version, and will neither be sold nor offered for purchase in the United States of America. The information contained in this document is not intended to be passed on into the USA or within the USA.

This document is directed at and/or for distribution in the U. K. only to (i) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (ii) high net worth entities falling within article 49(2)(a) to (d) of the Order (all such persons being together referred to as “relevant persons”). This document is directed only at relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. Any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons.

Back to Archive